Physician profile
Jennifer Marie Edwards
NPI 1801472436
$13,633.80
in general payments reported to CMS, 2019-2025
31 companies · $6,525 in 2025
The $6,525 reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $573 · 2022: $803 · 2023: $2,548 · 2024: $3,185 · 2025: $6,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,660 · Consulting Fee: $2,490 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,660.13 |
| Consulting Fee | $2,490.00 |
| Education | $108.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $2,708.66 | 2023-2025 | Zoryve |
| Abbvie INC. | $2,227.06 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,754.21 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $932.76 | 2021-2025 | Winlevi, Absorica Ld, Blu-U |
| Incyte Corporation | $693.20 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $619.98 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $586.18 | 2021-2025 | Dupixent, Libtayo |
| Mayne Pharma Commercial LLC | $485.14 | 2021-2025 | |
| Dermavant Sciences, INC. | $418.15 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $409.62 | 2024-2025 | Nemluvio, Aklief, Dysport |
| Pfizer INC. | $380.15 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $364.24 | 2021-2025 | Arazlo, Cabtreo, Jublia |
| Janssen Biotech, INC. | $331.12 | 2023-2025 | Tremfya |
| Lilly USA, LLC | $322.26 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Genzyme Corporation | $302.95 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $159.20 | 2022-2025 | |
| Verrica Pharmaceuticals INC. | $147.60 | 2023-2024 | Ycanth |
| Leo Pharma INC. | $146.75 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $122.66 | 2022-2025 | Otezla |
| Organon LLC | $92.48 | 2025 | Vtama |
| Ucb, INC. | $91.67 | 2021-2025 | Bimzelx |
| Kyowa Kirin, INC. | $70.13 | 2022-2025 | Poteligeo |
| Epi Health, LLC | $52.26 | 2021 | |
| Almirall LLC | $47.46 | 2023-2025 | Seysara |
| Genentech USA, INC. | $43.45 | 2025 | Xolair |
| Lnhc, INC | $36.63 | 2025 | Zelsuvmi |
| Botanix Sb INC | $29.91 | 2025 | Sofdra |
| Biofrontera INC. | $16.02 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Helsinn Therapeutics (U.S.), INC. | $14.50 | 2021 | |
| Strata Skin Sciences, INC. | $14.23 | 2025 | Xtrac |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.